共 54 条
- [1] Mittal S(2013)Epidemiology of hepatocellular carcinoma: consider the population J Clin Gastroenterol 47 S2-6
- [2] El-Serag HB(2015)Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study Liver Int 35 2155-2166
- [3] Park JW(2015)Cancer immunotherapy: harnessing the immune system to battle cancer J Clin Invest 125 3335-3337
- [4] Chen M(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264
- [5] Colombo M(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma N Engl J Med 382 1894-1905
- [6] Yang Y(2021)Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study Liver Cancer 10 107-114
- [7] Pardoll DM(2018)A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors J Immunother Cancer 6 128-3534
- [8] Finn RS(2019)First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis Cancer 125 3526-11
- [9] Qin S(2018)Immune checkpoint inhibitors: recent progress and potential biomarkers Exp Mol Med 50 1-S10
- [10] Ikeda M(2019)Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges Oncologist 24 S3-60